Galapagos increases share capital through warrant exercises
(Thomson Reuters ONE) -
Mechelen, Belgium; 4 December 2015 - Galapagos NV (Euronext & NASDAQ: GLPG)
announced a share capital increase arising from warrant exercises.
Galapagos issued 63,500 new ordinary shares on 4 December 2015, for a total
capital increase (including issuance premium) of ?590,800.00.
Pursuant to the rules of the warrant exercise program of Galapagos' Executive
Committee adopted in 2013, Executive Committee members automatically are
committed to exercise a minimum number of warrants, subject to certain
conditions. Accordingly, CEO Onno van de Stolpe exercised 10,000 warrants and
has consequently increased his holding to a total of 538,289 shares; two other
Executive Committee members exercised an aggregate amount of 5,000 warrants.
In accordance with Belgian transparency legislation[1], Galapagos notes that its
total share capital currently amounts to ? 211,388,857.22; the total number of
securities conferring voting rights is 39,076,342, which is also the total
number of voting rights (the "denominator"), and all securities conferring
voting rights and all voting rights are of the same category. The total number
of rights (warrants) to subscribe to not yet issued securities conferring voting
rights is 2,805,692, which equals the total number of voting rights that may
result from the exercise of these warrants. Galapagos does not have any
convertible bonds or shares without voting rights outstanding.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises three Phase 2, three Phase 1 and
five pre-clinical, and 20 discovery studies in cystic fibrosis, inflammation,
fibrosis, osteoarthritis and other indications. We are focused on the
development and commercialization of novel medicines that will improve people's
lives. The Galapagos group, including fee-for-service subsidiary Fidelta has
approximately 400 employees, operating from its Mechelen, Belgium headquarters
and facilities in The Netherlands, France, and Croatia. More information at
www.glpg.com.
Contacts
Investors: Media:
Elizabeth Goodwin Evelyn Fox
VP IR & Corporate Communications Director Communications
Tel:
+1 781 460 1784 Tel: +31 6 53 591 999
ir(at)glpg.com communications(at)glpg.com
Forward-looking statements
This release may contain forward-looking statements, all of which involve
certain risks and uncertainties. These statements are often, but not always,
made through the use of words or phrases such as "anticipates," "believes,"
"continues," "could," "estimates," "expects," "intends," "may," "plans,"
"seeks," "stands to," "we believe," "will," "we intend," as well as similar
expressions. Such forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual results, financial
condition and liquidity, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future results,
financial conditions and liquidity, performance or achievements expressed or
implied by such forward-looking statements. In addition, even if Galapagos'
results, performance, financial condition and liquidity, and the development of
the industry in which it operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future
periods. Among the factors that may result in differences are the inherent
uncertainties associated with competitive developments, clinical trial and
product development activities and regulatory approval requirements (including
that data from Galapagos' ongoing clinical research programs may not support
registration or further development of its product candidates due to safety,
efficacy or other reasons), Galapagos' reliance on collaborations with third
parties, and estimating the commercial potential of Galapagos' product
candidates. A further list and description of these risks, uncertainties and
other risks can be found in Galapagos' Securities and Exchange Commission (SEC)
filings and reports, including in Galapagos' prospectus filed with the SEC on
14 May 2015 and future filings and reports filed by Galapagos with the SEC.
Given these uncertainties, the reader is advised not to place any undue reliance
on such forward-looking statements. These forward-looking statements speak only
as of the date of publication of this document. Galapagos expressly disclaims
any obligation to update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based or that
may affect the likelihood that actual results will differ from those set forth
in the forward-looking statements, unless specifically required by law or
regulation.
--------------------------------------------------------------------------------
[1] Belgian Act of 2 May 2007 on the disclosure of major shareholdings in
issuers whose shares are admitted to trading on a regulated market
GLPG increases share capital through warrant exercises:
http://hugin.info/133350/R/1971576/720944.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
[HUG#1971576]
Unternehmensinformation / Kurzprofil:
Datum: 04.12.2015 - 22:00 Uhr
Sprache: Deutsch
News-ID 437751
Anzahl Zeichen: 6644
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 335 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos increases share capital through warrant exercises"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
